DK0667959T3 - Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid - Google Patents

Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid

Info

Publication number
DK0667959T3
DK0667959T3 DK93921300T DK93921300T DK0667959T3 DK 0667959 T3 DK0667959 T3 DK 0667959T3 DK 93921300 T DK93921300 T DK 93921300T DK 93921300 T DK93921300 T DK 93921300T DK 0667959 T3 DK0667959 T3 DK 0667959T3
Authority
DK
Denmark
Prior art keywords
beta
amyloid peptide
production
methods
identifying inhibitors
Prior art date
Application number
DK93921300T
Other languages
Danish (da)
English (en)
Inventor
Dale B Schenk
Peter A Seubert
Michael G Schlossmacher
J Selkoe Dennis
Carmen Vigo-Pelfrey
Original Assignee
Elan Pharm Inc
Brigham & Womens Hospital
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0667959(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc, Brigham & Womens Hospital, Lilly Co Eli filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of DK0667959T3 publication Critical patent/DK0667959T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
DK93921300T 1992-10-26 1993-09-01 Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid DK0667959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96597292A 1992-10-26 1992-10-26
PCT/US1993/008264 WO1994010569A1 (en) 1992-10-26 1993-09-01 METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE

Publications (1)

Publication Number Publication Date
DK0667959T3 true DK0667959T3 (da) 2003-12-08

Family

ID=25510753

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93921300T DK0667959T3 (da) 1992-10-26 1993-09-01 Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid
DK02079139.8T DK1298436T3 (da) 1992-10-26 1993-09-01 Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02079139.8T DK1298436T3 (da) 1992-10-26 1993-09-01 Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)

Country Status (9)

Country Link
EP (2) EP0667959B1 (de)
JP (2) JP3553592B2 (de)
AT (2) ATE474224T1 (de)
CA (1) CA2105903C (de)
DE (3) DE667959T1 (de)
DK (2) DK0667959T3 (de)
ES (2) ES2346852T3 (de)
PT (2) PT1298436E (de)
WO (1) WO1994010569A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT620849E (pt) * 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
PT730643E (pt) 1993-10-27 2001-06-29 Lilly Co Eli Animais transgenicos portadores do alelo de app com mutacao sueca
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5484940A (en) * 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
US6096782A (en) 1996-11-22 2000-08-01 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6642261B2 (en) 1997-11-21 2003-11-04 Athena Neurosciences, Inc. N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6117901A (en) 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR20010033408A (ko) * 1997-12-22 2001-04-25 진 엠. 듀발 폴리시클릭 α-아미노-ε-카프롤락탐 및 관련 화합물
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
JP5122705B2 (ja) * 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1481992T3 (en) * 2000-02-24 2017-01-30 Washington Univ St Louis Humanized antibodies which sequester amyloid beta peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1424892A4 (de) * 2001-08-10 2006-08-23 Univ South Florida Modulation der angiogenese durch a-beta-peptide
WO2003015617A2 (en) * 2001-08-17 2003-02-27 Washington University Assay method for alzheimer's disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005009344A2 (en) 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
WO2005095958A1 (ja) 2004-03-31 2005-10-13 Angesmg, Inc. 薬剤候補を同定するためのアッセイ法
ATE549404T1 (de) 2004-10-01 2012-03-15 Takeda Pharmaceutical Verfahren zum screening eines transmembranenzymhemmstoffs
US20090123952A1 (en) * 2004-11-12 2009-05-14 Pfizer, Inc. Method of Measuring Amyloid-Beta Peptides
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
EP1951750A4 (de) 2005-11-10 2009-12-09 Roskamp Res Llc Modulation der angiogenese durch a-beta-peptidfragmente
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8986657B2 (en) 2009-07-31 2015-03-24 The General Hospital Corporation Methods and system for detecting soluble amyloid-β
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
CN102955014B (zh) * 2012-10-19 2014-12-31 上海吉尔多肽有限公司 一种Aβ-淀粉样多肽1-42纯度的检测方法
JP6989927B2 (ja) * 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
CN105153273A (zh) * 2015-08-25 2015-12-16 苏州强耀生物科技有限公司 一种制备β-淀粉样多肽1-40纯品的方法
CN109696550B (zh) * 2017-10-20 2022-08-26 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体液样品稳定化用水溶液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
DE69133372T2 (de) * 1990-06-15 2005-02-24 Scios Inc., Sunnyvale Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein

Also Published As

Publication number Publication date
DE69333144T2 (de) 2004-05-19
PT667959E (pt) 2003-12-31
ES2203620T3 (es) 2004-04-16
DE667959T1 (de) 2000-04-20
AU687747B2 (en) 1998-03-05
ATE474224T1 (de) 2010-07-15
AU4844493A (en) 1994-05-24
EP0667959A1 (de) 1995-08-23
JP3553592B2 (ja) 2004-08-11
CA2105903A1 (en) 1994-04-27
ATE247282T1 (de) 2003-08-15
JPH08502587A (ja) 1996-03-19
JP2004121251A (ja) 2004-04-22
ES2346852T3 (es) 2010-10-21
CA2105903C (en) 2011-11-01
EP1298436A3 (de) 2003-07-09
WO1994010569A1 (en) 1994-05-11
DE69334337D1 (de) 2010-08-26
EP0667959B1 (de) 2003-08-13
JP3694303B2 (ja) 2005-09-14
EP0667959A4 (de) 1998-07-08
DE69333144D1 (de) 2003-09-18
DK1298436T3 (da) 2010-10-25
EP1298436A2 (de) 2003-04-02
PT1298436E (pt) 2010-10-21
EP1298436B1 (de) 2010-07-14

Similar Documents

Publication Publication Date Title
DK0667959T3 (da) Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid
Ross Vitamin B12 assay in body fluids using Euglena gracilis
Dowdle, EB, Mustard, P. & Eales d-Aminolaevulinic acid synthetase activity in normal and porphyric human livers
Sieber et al. Dye-mediated photosensitization of murine neuroblastoma cells
ATE287660T1 (de) Vorrichtung zum detektieren eines analyten und zur verabreichung einer therapeutischen substanz
ES2052766T3 (es) Composiciones magneticas en estado liquido.
Jeste et al. A biochemical study of tardive dyskinesia in young male patients
FR2666096B1 (fr) Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
Jepson et al. Decreased in vivo and in vitro erythropoiesis induced by plasma of ten patients with thymoma, lymphosarcoma, or idiopathic erythroblastopenia
Szilagyi et al. The anticryptococcal factor of blood serum
FI941920A (fi) Menetelmä ja koostumus bioaktiivisten substanssien immunologisen aktiivisuuden määrittämiseksi
ATE382678T1 (de) Verfahren zur diagnose von rickettsia pulicis
Lau et al. Mucopolysaccharide synthesis by human bone marrow in short-term suspension cultures
Piasecki et al. Continuous intraoperative monitoring of hepatic blood perfusion using a noninvasive surface electrode
Zinner et al. Cytotoxic effect of dental local anesthetics on tissue culture
Forgacs et al. Studies on streptomycin: III. Microtechniques for assay
SU1171711A1 (ru) Способ выбора анестезиологической тактики при подготовке детей с ревматоидным артритом к операции
Schwartz et al. Quantitative differentiation of minute amounts of the coproporphyrin isomers (I and III) based on fluorescence behavior
Linker et al. Polysaccharide of a mucoid E. coli isolated from a patient with cystic fibrosis
TOMOKUNI et al. The effect of exposing men and animals to lead on the pH activity curves of hepatic and erythrocyte δ-aminolaevulinate dehydratase
Wogan et al. Biological monitoring of environmental toxic chemicals.
Coleman et al. The Presence and Source of Ascorbic Acid in Hymenolepis nana var. fraterna (V. Siebold, 1852)
RU2136152C1 (ru) Способ определения естественной резистентности организма птиц
BROCKEMEYER A measurement of the efficiency of ointment bases in releasing a local anesthetic by using a pain threshold method
Aliu ABSORPTION, DISTRIBUTION, AND EXCRETION OF IMIDOCARB DIPROPIONATE (3, 3'-BIS-(2-IMIDAZOLIN-2-YL) CARBANILIDE) IN SHEEP.